Financial Gravity Asset Management’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-5
Closed -$316 1669
2024
Q1
$316 Buy
+5
New +$387 ﹤0.01% 1516
2023
Q1
Sell
-46
Closed -$1.35K 1264
2022
Q4
$1.35K Buy
+46
New +$1.98K 0.01% 608
2020
Q2
Sell
-25
Closed -$295 201
2020
Q1
$295 Sell
25
-69
-73% -$880 ﹤0.01% 648
2019
Q4
$11K Sell
94
-10
-10% -$103 0.01% 1172
2019
Q3
$1K Hold
104
﹤0.01% 1004
2019
Q2
$1K Hold
104
﹤0.01% 1025
2019
Q1
$1K Buy
+104
New +$765 ﹤0.01% 1069
2018
Q3
$1K Sell
109
-6
-5% -$48 ﹤0.01% 1103
2018
Q2
$1K Sell
115
-4
-3% -$33 ﹤0.01% 1127
2018
Q1
$1K Buy
+119
New +$1.02K ﹤0.01% 1101

Other funds holding CYTK

Financial Gravity Asset Management's CYTK Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 5 shares — an estimated $316 sold.

Financial Gravity Asset Management first reported a position in CYTK in Q1 2018 and held it in 10 quarters. The position peaked at $11K in Q4 2019. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 5 Cytokinetics shares in Q2 2024, an estimated $316.
  • Financial Gravity Asset Management first reported a position in Cytokinetics in Q1 2018 and held it in 10 quarters.
  • Financial Gravity Asset Management's Cytokinetics position peaked at $11K in Q4 2019.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.